Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of Escalating Single Doses of ITI-214 in Patients With Systolic Heart Failure
Phase of Trial: Phase I/II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ITI 214 (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- Sponsors Intra-Cellular Therapies
- 31 Aug 2018 Biomarkers information updated
- 24 Jul 2018 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 24 Jul 2018 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.